DKP Critical Insights® Syndicated Reports
DKP has developed a series of syndicated reports to provide perspectives into the oncology and rare-disease environment. The reports are designed to help you inform short- and long-term strategies that will support market positioning of your portfolio, as well as ongoing patient access to care.
State Biosimilars and Biologic Substitution Legislation
Click here for more information
- Utilize an interactive map to identify biosimilar and biologic substitution legislation for each of the 50 states, DC, and Puerto Rico
- Learn each state’s requirements for substituting a biosimilar with its reference product
- This report helps inform your products short-term and long-term strategies in regards to positioning your portfolio in alignment with the FDA’s focus on cost reduction, which includes the uptake and utilization of biosimilars